Clinical Trials

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06211335 2026-03-12

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

24 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06493019 2026-03-12

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

23 enrolled

Gastrointestinal

Anus Neoplasms

NCT07017829 2026-03-11

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

28 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04697576 2026-03-10

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

36 enrolled

Melanoma

NCT04712851 2026-03-10

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

25 enrolled

Gynecologic

Uterine Cervical Dysplasia

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT06771544 2026-03-10

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

14 enrolled

Melanoma

NCT05669846 2026-03-09

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

26 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT07448831 2026-03-09

NeoSenti

49 enrolled

Melanoma

NCT04253964 2026-03-06

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05188508 2026-03-06

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

57 enrolled

CNS

Glioma

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

MyeloidOther hematologic neoplasm

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05463848 2026-03-04

Surgical Pembro +/- Olaparib w TMZ for rGBM

78 enrolled

CNS

Glioblastoma

NCT05812807 2026-03-04

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT06661720 2026-03-04

STRIKE

1,040 enrolled

Carcinoma, Renal Cell

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

40 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05977907 2026-03-03

KIEO

30 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07343596 2026-03-03

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

Phase NA Recruiting

20 enrolled

Mouth Neoplasms

NCT07026474 2026-03-02

RePaIr-HN

214 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04134559 2026-02-24

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

18 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms

NCT05603910 2026-02-24

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

18 enrolled

Gynecologic

Endometrial Neoplasms

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

47 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT06976944 2026-02-23

PRELUDE

44 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT06475235 2026-02-20

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

15 enrolled

Lymphoid

Lymphoma

NCT07422779 2026-02-20

MAK

Phase NA Recruiting

100 enrolled

Melanoma, Skin Neoplasms

NCT05239624 2026-02-19

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

23 enrolled

Carcinoma, Transitional Cell

NCT06999980 2026-02-19

Neo IRENIE

494 enrolled

Melanoma

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Thyroid Neoplasms

NCT05496036 2026-02-18

MCC

15 enrolled

Carcinoma, Merkel Cell

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer